The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...

Greenwich LifeSciences (GLSI) announced the following update on FLAMINGO-01 open label safety data. The FLAMINGO-01 DSMB met twice in 2024, ...

Every investor in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual insiders ...

STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...

Greenwich LifeSciences, Inc. provided an update on its Phase III clinical trial, FLAMINGO-01, which is investigating the immunotherapy GLSI-100 for preventing breast cancer recurrences.

In other recent news, Greenwich LifeSciences, a clinical-stage biopharmaceutical company, has made significant strides in its ongoing operations. The company has expanded its Phase III trial ...

Explore Greenwich LifeSciences stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for GLSI. Greenwich Lifesciences shares are trading higher by 30.6% Wednesday ...

Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Greenwich LifeSciences, Inc. provided an update ...

About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in ...

STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...